Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? ClinNeuropathol 3: 185-192

Author(s): Kosaka K, Yoshimura M, Ikeda K, Budka H


The term Lewy body disease (LBD) was proposed earlier to describe a disease classified into three types (A, B, and C) according to the distributional pattern of Lewy bodies in the CNS. Group A (diffuse type of LBD) shows clinical symptoms of "dementia-parkinsonism syndrome". The most remarkable pathologic feature is the widespread appearance of numerous Lewy bodies not only in the brain stem and diencephalon (as in group C), but also in the cerebral cortex and basal ganglia, which is complicated by senile changes of various degrees. Group B is the transitional type between groups A and C. Group C (brain stem type of LBD) is identical with idiopathic Parkinson's disease. In this paper, 12 of our cases with diffuse type LBD were studied clinicopathologically and compared with eight similar cases in the literature. The neuropathologic substrate of progressive dementia in this disease is also discussed. LBD is a clinicopathologic entity; the diffuse type of LBD, a special form of this disease, presents mainly a presenile dementia.

Similar Articles

Diffuse Lewy body disease and progressive dementia

Author(s): Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, et al.

Low sensitivity in clinical diagnoses of dementia with Lewy bodies

Author(s): Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, et al.

Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies

Author(s): Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, et al.

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

Author(s): Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, et al.

A clinicopathologic study of 100 cases of Parkinson's disease

Author(s): Hughes AJ, Daniel SE, Blankson S, Lees AJ

Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP

Author(s): Hu WT, Watts K, Grossman M, Glass J, Lah JJ, et al.

Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies

Author(s): Cagnin A, Gnoato F, Jelcic N, Favaretto S, Zarantonello G, et al.

Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies

Author(s): Hamilton JM, Salmon DP, Galasko D, Raman R, Emond J, et al.

Amyloid imaging of Lewy body-associated disorders

Author(s): Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, et al.